We next explored the effects of the combination in RAS pathway mutant models that are intrinsically resistant to MEK inhibition, such as the MM cell line RPMI-8226 and the SCLC cell line NCI-H510 (Fig. 2d, Supplemental Figure S10A). This evidence concerns the gene MAP2K7 and small cell lung carcinoma.